The Combination of RET, BRAF and Demographic Data Identifies Subsets of Patients with Aggressive Papillary Thyroid Cancer

Patient Age–Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer

(2018) Xiaopei Shen et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic effects ofTERTpromoter mutations are enhanced by coexistence withBRAForRASmutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients

(2016) Young Shin Song et al.   CANCER

Meta-Analyses of Association Between BRAFV600E Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma

(2016) Qing Zhang et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation

(2016) Ja Seong Bae et al.   Diagnostic Pathology

Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data

(2016) Young Jun Chai et al.   PLoS One

An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer

(2016) Iain J. Nixon et al.   THYROID

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

(2016) Bryan R. Haugen et al.   THYROID

BRAFV600E Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer

(2016) S. Fraser et al.   WORLD JOURNAL OF SURGERY

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients

(2016) Jian Sun et al.   PLoS One

BRAF overexpression is associated with BRAF V600E mutation in papillary thyroid carcinomas

(2015) R.C. da Silva et al.   GENETICS AND MOLECULAR RESEARCH

Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer

(2015) Mingzhao Xing et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of haem oxygenase-1 correlates with tumour aggressiveness and BRAFV600Eexpression in thyroid cancer

(2014) Tao-Yeuan Wang et al.   HISTOPATHOLOGY

The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways

(2014) Susi Barollo et al.   INVESTIGATIONAL NEW DRUGS

TERTPromoter Mutations and Their Association withBRAFV600E Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer

(2014) Xiaoli Liu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence

(2014) Mingzhao Xing et al.   JOURNAL OF CLINICAL ONCOLOGY

MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights

(2014) Matthias S Dettmer et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Concomitant RAS, RET/PTC, or BRAF Mutations in Advanced Stage of Papillary Thyroid Carcinoma

(2014) Minjing Zou et al.   THYROID

Notch Pathway Is Activated by MAPK Signaling and Influences Papillary Thyroid Cancer Proliferation

(2014) Alex Shimura Yamashita et al.   Translational Oncology

MicroRNAs used as novel biomarkers for detecting cancer metastasis

(2014) Chunshan Han et al.   TUMOR BIOLOGY

Allele Percentage of theBRAFV600E Mutation in Papillary Thyroid Carcinomas and Corresponding Lymph Node Metastases: No Evidence for a Role in Tumor Progression

(2013) Greta Gandolfi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Clinical Significance of BRAF Mutation in Thyroid Papillary Cancer

(2013) Ignacio J. Fernandez et al.   OTOLARYNGOLOGY-HEAD AND NECK SURGERY

Concomitant BRAFV600E Mutation and RET/PTC Rearrangement Is a Frequent Occurrence in Papillary Thyroid Carcinoma

(2013) Anna Guerra et al.   THYROID

BRAFV600E Mutation Analysis in Papillary Thyroid Carcinoma: Is it Useful for all Patients?

(2013) Yasuhiro Ito et al.   WORLD JOURNAL OF SURGERY

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma

(2013) GUOPING HE et al.   Oncology Letters

Expression analysis of B-Raf oncogene in V600E-negative benign and malignant tumors of the thyroid gland: correlation with late disease onset

(2012) Stavros P. Derdas et al.   MEDICAL ONCOLOGY

mRNA BRAF expression helps to identify papillary thyroid carcinomas in thyroid nodules independently of the presence of BRAFV600E mutation

(2012) Priscila Pereira Costa Araujo et al.   PATHOLOGY RESEARCH AND PRACTICE

Intracellular Signal Transduction and Modification of the Tumor Microenvironment Induced by RET/PTCs in Papillary Thyroid Carcinoma

(2012) Elisa Menicali et al.   Frontiers in Endocrinology

The Primary Occurrence ofBRAFV600EIs a Rare Clonal Event in Papillary Thyroid Carcinoma

(2011) Anna Guerra et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Overexpression of wild-type c-RET and zero prevalence of RET/PTC rearrangements are associated with papillary thyroid cancer (PTC) in Kuwait

(2010) Abir A. El-Abdallah et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Prognostic utility of BRAF mutation in papillary thyroid cancer

(2009) Mingzhao Xing   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer

(2009) David S. Cooper et al.   THYROID